SEC Form 4 · accession 0001209191-18-036228

REATA PHARMACEUTICALS INC · RETA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Development Officer

Period of report

Jun 5, 2018

Accepted (ET)

Jun 7, 2018 · 11:37 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001358762

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Class A common stock^F2	Jun 5, 2018	C	28,500	—	A	28,500	D
Class A common stock	Jun 5, 2018	S	28,500	$36.62	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F3	$11.62	Jun 5, 2018	M	28,500	D	—	Jun 15, 2023	Class B common stock	28,500	53,787	D
Class B common stock^F2	—	Jun 5, 2018	M	28,500	A	—	—	Class A common stock	28,500	28,500	D
Class B common stock^F2	—	Jun 5, 2018	C	28,500	D	—	—	Class A common stock	28,500	0	D

F1The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017.
F2The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
F3The option, representing a right to purchase a total of 82,287 shares, vests in twenty equal quarterly installments beginning September 15, 2013, subject to continued service through each vesting date.